marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q3
added 11-09-2023
NeuBase Therapeutics Balance Sheet 2011-2024 | NBSE
Annual Balance Sheet NeuBase Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-52.4 M | -31.9 M | -10.2 M | -3.68 M | -12.7 M | -12.5 M | -28.6 M | -13.2 M | -5.11 M | -2.61 M | -470 K | |
Long Term Debt |
- | 110 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
553 K | 383 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 150 K | - | - | - | - | - | - |
Total Current Liabilities |
4.17 M | 4.19 M | - | - | 725 K | 4.93 M | 4.48 M | 3.88 M | 5.27 M | 480 K | 1.09 M | 6.19 M |
Total Liabilities |
9.5 M | 10.1 M | 3.15 M | 2.5 M | 725 K | 5.08 M | 4.48 M | 3.88 M | 5.27 M | 480 K | 1.09 M | 6.19 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-103 M | -69 M | -43.6 M | -27 M | -121 M | -108 M | -84.3 M | -58.5 M | -43.3 M | -21.6 M | -28.5 M | -21.6 M |
Total Assets |
32.7 M | 64.2 M | 34.4 M | 12.5 M | 11.6 M | 27.9 M | 29.4 M | 46.4 M | 32 M | 5.74 M | 3.52 M | 1.41 M |
Cash and Cash Equivalents |
23.2 M | 52.9 M | 32 M | 10.3 M | 250 K | 12.8 M | 12.5 M | 28.7 M | 13.2 M | 5.12 M | 2.63 M | 470 K |
Book Value |
23.2 M | 54.1 M | 31.3 M | 10 M | 10.9 M | 22.8 M | 25 M | 42.5 M | 26.8 M | 5.26 M | 2.43 M | -4.78 M |
Total Shareholders Equity |
23.2 M | 54.1 M | 31.3 M | 10 M | -41.9 K | 22.8 M | 25 M | 42.5 M | 26.8 M | 5.26 M | 2.43 M | -4.78 M |
All numbers in USD currency
Quarterly Balance Sheet NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
4.83 M | 4.96 M | 5.09 M | 5.21 M | 5.34 M | 20.1 K | 49.8 K | 79 K | 110 K | 5.9 M | 110 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 250 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.86 M | - |
Total Liabilities |
9.48 M | 11.1 M | 7.01 M | 7.36 M | 9.5 M | 9.68 M | 10.6 M | 9.91 M | 10.1 M | 9.04 M | 10.1 M | 2.24 M | 3.15 M | 3.15 M | 3.15 M | 2.85 M | 2.5 M | 2.5 M | 2.5 M | 530 K | 291 K | 725 K | 597 K | 3.75 M | 5.08 M | 5.08 M | 5.08 M | 3.89 M | 4.48 M | 4.48 M | 4.48 M | 5.28 M | 3.88 M | 3.88 M | 3.88 M | 6.78 M | 5.27 M | 5.27 M | 5.27 M | 250 K | 480 K | 480 K | 480 K | 2.38 M | 1.09 M | 1.09 M | 1.09 M | 5.53 M | 6.19 M | 6.19 M | 6.19 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-116 M | -115 M | -111 M | -107 M | -103 M | -95.1 M | -86.6 M | -76.7 M | -69 M | -61.8 M | -69 M | -47.6 M | -43.6 M | -43.6 M | -43.6 M | -31.5 M | -26.2 M | -27 M | -27 M | -1.53 M | -42 K | -121 M | -122 M | -112 M | -108 M | -108 M | -108 M | -91.3 M | -84.3 M | -84.3 M | -84.3 M | -64.7 M | -58.5 M | -58.5 M | -58.5 M | -47.9 M | -43.3 M | -43.3 M | -43.3 M | -21.6 M | -34.2 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M |
Total Assets |
18.6 M | 22.3 M | 21.5 M | 25.6 M | 32.7 M | 40 M | 48.8 M | 57 M | 64.2 M | 69.3 M | 64.2 M | 30.8 M | 34.4 M | 34.4 M | 34.4 M | 9.88 M | 12.5 M | 12.5 M | 12.5 M | 137 K | 250 K | 11.6 M | 10.7 M | 23.4 M | 27.9 M | 27.9 M | 27.9 M | 29.7 M | 29.4 M | 29.4 M | 29.4 M | 44.2 M | 46.4 M | 46.4 M | 46.4 M | 29.4 M | 32 M | 32 M | 32 M | 4.59 M | 5.74 M | 5.74 M | 5.74 M | 2.92 M | 3.52 M | 3.52 M | 3.52 M | 2.07 M | 1.41 M | 1.41 M | 1.41 M |
Cash and Cash Equivalents |
12.6 M | 14.7 M | 13.8 M | 17.4 M | 23.2 M | 29.8 M | 39 M | 47.3 M | 52.9 M | 58.8 M | 52.9 M | 32 M | 32 M | 32 M | 28 M | 7.73 M | 10.3 M | 10.3 M | 7.73 M | 137 K | 250 K | 3.75 M | 3.11 M | 8.72 M | 12.8 M | 12.8 M | 12.8 M | 13.5 M | 12.5 M | 12.5 M | 12.5 M | 25.3 M | 28.7 M | 28.7 M | 28.7 M | 10.4 M | 13.2 M | 13.2 M | 10.4 M | 4.02 M | 5.12 M | 5.12 M | 4.02 M | 2.07 M | 2.63 M | 2.63 M | 2.07 M | 1.26 M | 470 K | 470 K | 1.26 M |
Book Value |
9.14 M | 11.2 M | 14.4 M | 18.2 M | 23.2 M | 30.3 M | 38.2 M | 47.1 M | 54.1 M | 60.3 M | 54.1 M | 28.5 M | 31.3 M | 31.3 M | 31.3 M | 7.03 M | 10 M | 10 M | 10 M | -392 K | -41.9 K | 10.9 M | 10.1 M | 19.7 M | 22.8 M | 22.8 M | 22.8 M | 25.8 M | 25 M | 25 M | 25 M | 38.9 M | 42.5 M | 42.5 M | 42.5 M | 22.6 M | 26.8 M | 26.8 M | 26.8 M | 4.34 M | 5.26 M | 5.26 M | 5.26 M | 540 K | 2.43 M | 2.43 M | 2.43 M | -3.45 M | -4.78 M | -4.78 M | -4.78 M |
Total Shareholders Equity |
9.14 M | 11.2 M | 14.4 M | 18.2 M | 23.2 M | 30.3 M | 38.2 M | 47.1 M | 54.1 M | 60.3 M | 23.9 M | 28.5 M | 31.3 M | 28.5 M | 28.5 M | 7.03 M | 10 M | 7.03 M | 7.03 M | -392 K | 10.1 M | 10.1 M | 10.1 M | 19.7 M | 22.8 M | 22.8 M | 19.7 M | 25.8 M | 25 M | 25 M | 25 M | 38.9 M | 42.5 M | 42.5 M | 42.5 M | 22.6 M | 26.8 M | 26.8 M | 26.8 M | 4.34 M | 5.26 M | 5.26 M | 5.26 M | 540 K | 2.43 M | 2.43 M | 2.43 M | -3.45 M | -4.78 M | -4.78 M | -4.78 M |
All numbers in USD currency